301-400

301. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.

302. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation

myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-1232.

303. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing

percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.

304. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized

controlled trial. JAMA 2002; 288: 2411-2420.

305. Isshiki T, Kimura T, Ueno T, et al. Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial

infarction (CLEAN). Int Heart J 2012; 53: 91-101.

306. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals

undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:

1233-1243.

307. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation

acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing

Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938.

308. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American

College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and

Interventions. J Am Coll Cardiol 2011; 58: e44-122.

309. Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119:

987- 995.

310. Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and long-term clinical outcome after sirolimus-eluting stent implantation: 5-year

outcome of the j-Cypher registry. Cardiovasc Interv Ther 2012; 27: 181-188.

311. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet

therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll

Cardiol 2008; 52: 1502-1517.

312. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors

and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet

therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;

122: 2619-2633.

313. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following

acute coronary syndrome. JAMA 2009; 301: 937-944.

314. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;

180: 713-718.

315. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the

clopidogrel Medco outcomes study. Pharmacotherapy 2010; 30: 787-796.

316. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-

pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.

317. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.

318. Chitose T, Hokimoto S, Oshima S, et al. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump

inhibitor. Circ J 2012; 76: 71-78.

319. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin

(FAMOUS): a phase III, randomised, doubleblind, placebo-controlled trial. Lancet 2009; 374: 119-125.

320. Ochiai M, Eto K, Takeshita S, et al. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.

Am J Cardiol 1999; 84: 1074-1076, A1076, A1079.

321. Takeyasu N, Watanabe S, Noguchi Y, et al. Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Circ J

2005; 69: 780-785.

322. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute

myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-1826.

323. Kasama S, Toyama T, Hatori T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular

remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007; 49: 667-674.

324. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial

infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-1493.

325. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused

anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.

326. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-

elevation myocardial infarction. Circulation 2005; 112: 1284-1288.

327. Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009; 73: 925-931.

328. Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow

and functional improvement in patients with acute myocardial infarction. Am Heart J 1997; 133: 616-621.

329. Ito N, Nanto S, Doi Y, et al. High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be

improved by intracoronary administration of nicorandil. Circ J 2010; 74: 909-915.

330. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a

multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34:

1711-1720.

331. Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet 2006; 367: 456-458.

332. Higuma T, MatsunagaT, Maeda N, et al. Early statin treatment before coronary intervention protects against reperfusion injury and reduces infarct size

in patients with acute myocardial infarction. Circulation 2005; 112: II-569. Abstract.

333. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 2006; 70: 832-837.

334. 心筋梗塞患者に対するエポエチンベータ投与による心機能改善効果に関する研究-II. http://www.epoami2.com/（2012年12月閲覧）

335. Libby P, Bonow RO, Mann DL, et al. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (9th edition), Saunders 2011: 1119.

336. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev 1999; 79: 917-1017.

337. Akar FG, Aon MA, Tomaselli GF, et al. The mitochondrial origin of postischemic arrhythmias. J Clin Invest 2005; 115: 3527-3535.

338. Majidi M, Kosinski AS, Al-Khatib SM, et al. Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with

primary angioplasty for anterior ST-elevation myocardial infarction. Eur Heart J 2009; 30: 757-764.

339. Bonnemeier H, Wiegand UK, Giannitsis E, et al. Temporal repolarization inhomogeneity and reperfusion arrhythmias in patients undergoing successful

primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: impact of admission troponin T. Am Heart J 2003;

145: 484-492.

340. Terkelsen CJ, Sorensen JT, Kaltoft AK, et al. Prevalence and significance of accelerated idioventricular rhythm in patients with ST-elevation myocardial

infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2009; 104: 1641-1646.

341. Corr PB, Witkowski FX. Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium.

Circulation 1983; 68: I16-24.

342. Chiladakis JA, Vlachos N, Patsouras N, et al. Usefulness of reperfusion ventricular arrhythmias in non-invasive prediction of early reperfusion and

sustained coronary artery patency in acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 231-236.

343. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary

percutaneous coronary intervention. JAMA 2009; 301: 1779-1789.

344. Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction. A meta-analysis.

Circulation 1993; 88: 2575-2581.

345. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the

randomized, controlled trials. JAMA 1988; 260: 1910-1916.

346. 日本腎臓病学会，日本医学放射線学会，日本循環器学会．腎障害患者におけるヨード造影剤使用に関するガイドライン2012．東京医学社 2012．

347. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation

2002; 105: 2259-2264.

348. Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med

1989; 86: 649-652.

349. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

350. Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing

percutaneous coronary interventions. J Am Coll Cardiol 2011; 58: 907-914.

351. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:

development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399.

352. Brown JR, DeVries JT, Piper WD, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 2008; 155:

260-266.

353. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 1981; 136: 859-

861.

354. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.

Nephron Clin Pract 2003; 93: C29-34.

355. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrastinduced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA

2004; 291: 2328-2334.

356. Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65: 1366-1374.

357. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing

coronary angiography or intervention. Circulation 2004; 110: 2837-2842.

358. Morikawa S, Sone T, Tsuboi H, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am

Coll Cardiol 2009; 53: 1040-1046.

359. Lehnert T, Keller E, Gondolf K, et al. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial

Transplant 1998; 13: 358-362.

360. Huber W, Jeschke B, Kreymann B, et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely

impaired renal function, comparison with patients at similar risk and review. Invest Radiol 2002; 37: 471-481.

361. Kawashima S, Takano H, Iino Y, et al. Prophylactic hemodialysis does not prevent contrast-induced nephropathy after cardiac catheterization in

patients with chronic renal insufficiency. Circ J 2006; 70: 553-558.

362. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful.

Am J Med 2001; 111: 692-698.

363. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast

agents. N Engl J Med 1994; 331: 1416-1420.

364. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A

population-based, nested case-control analysis. Am J Epidemiol 2006; 164: 881-889.

365. Day HW. An Intensive Coronary Care Area. Dis Chest 1963; 44: 423-426.

366. Ross MA, Amsterdam E, Peacock WF, et al. Chest pain center accreditation is associated with better performance of centers for Medicare and

Medicaid services core measures for acute myocardial infarction. Am J Cardiol 2008; 102: 120-124.

367. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific

statement from the American Heart Association. Circulation 2010; 122: 1756-1776.

368. 日本集中治療医学会集中治療部施設設置基準検討委員会．CCU設置のための指針．日集中医誌 2004; 11: 259-267.

369. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive

summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to

Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.

370. Lee TH, Goldman L. The coronary care unit turns 25: historical trends and future directions. Ann Intern Med 1988; 108: 887-894.

371. Swan HJ, Ganz W. Measurement of right atrial and pulmonary arterial pressures and cardiac output: clinical application of hemodynamic monitoring.

Adv Intern Med 1982; 27: 453-473.

372. 石川欽司，金政健，林孝浩，他．急性心筋梗塞死亡率最近の低下．心臓 2002; 34: 533-542.

373. Lieu TA, Gurley RJ, Lundstrom RJ, et al. Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary. J Am Coll

Cardiol 1996; 27: 737-750.

374. Gust R, Gust A, Bottiger BW, et al. Bedside troponin T testing is not useful for early out-of-hospital diagnosis of myocardial infarction. Acta

Anaesthesiol Scand 1998; 42: 414-417.

375. Schuchert A, Hamm C, Scholz J, et al. Prehospital testing for troponin T in patients with suspected acute myocardial infarction. Am Heart J 1999;

138: 45-48.

376. Amar D, Greenberg MA, Menegus MA, et al. Should all patients undergoing cardiac catheterization or percutaneous transluminal coronary angioplasty

receive oxygen? Chest 1994; 105: 727-732.

377. Herkner H, Thoennissen J, Nikfardjam M, et al. Short versus prolonged bed rest after uncomplicated acute myocardial infarction: a systematic review

and meta-analysis. J Clin Epidemiol 2003; 56: 775-781.

378. Kawano Y, Ando K, Matsuura H, et al. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) Rationale

for salt restriction and salt-restriction target level for the management of hypertension. Hypertens Res 2007; 30: 879-886.

379. Warren SE, Alpert JS, Francis GS. Diet in the coronary care unit. Am Heart J 1978; 95: 130-131.

380. Cohen IM, Alpert JS, Francis GS, et al. Safety of hot and cold liquids in patients with acute myocardial infarction. Chest 1977; 71: 450-452.

381. 田中啓治．急性心筋梗塞における糖代謝異常の発現機序～特に心血行動態との関孫について．日医大誌 1985; 52: 49-57.

382. Opie LH. Provision of carbohydrate in acute MI. Am Heart J 1979; 97: 268-269.

383. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.

384. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with

acute myocardial infarction. JAMA 2009; 301: 1556-1564.

385. Reilly L, Sullivan P, Ninni S, et al. Reducing foley catheter device days in an intensive care unit: using the evidence to change practice. AACN Adv Crit

Care 2006; 17: 272-283.

386. Singman H, Kinsella E, Goldberg E. Electrocardiographic changes in coronary care unit patients during defecation. Vasc Surg 1975; 9: 54-57.

387. Stern TA. Psychiatric management of acute myocardial infarction in the coronary care unit. Am J Cardiol 1987; 60: 59J-67J.

388. Cassem NH, Hackett TP. Psychiatric consultation in a coronary care unit. Ann Intern Med 1971; 75: 9-14.

389. Broadbent E, Petrie KJ, Ellis CJ, et al. Patients with acute myocardial infarction have an inaccurate understanding of their risk of a future cardiac

event. Intern Med J 2006; 36: 643-647.

390. Arefjord K, Hallaraker E, Havik OE, et al. Illness understanding, causal attributions and emotional reactions in wives of myocardial infarction patients.

Psychol Psychother 2002; 75: 101-114.

391. 水野宣英．疾患・年齢・性別によるCCU滞在日数と死亡率について．ICUとCCU 2003; 27: 554-557.

392. Bjorklund E, Jernberg T, Johanson P, et al. ASSENT-2 and ASSENT-PLUS Study Groups. Admission N-terminal pro-brain natriuretic peptide and its

interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart 2006; 92: 735-

740.

393. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial

infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44: 335-339.

394. Giannitsis E, Lehrke S, Wiegand UK, et al. Risk stratification in patients with inferior acute myocardial infarction treated by percutaneous coronary

interventions: the role of admission troponin T. Circulation 2000; 102: 2038-2044.

395. Matetzky S, Sharir T, Domingo M, et al. Elevated troponin I level on admission is associated with adverse outcome of primary angioplasty in acute

myocardial infarction. Circulation 2000; 102: 1611-1616.

396. Hao K, Yasuda S, Takii T, et al. Urbanization, life style changes and the incidence/in-hospital mortality of acute myocardial infarction in Japan: report

from the MIYAGI-AMI Registry Study. Circ J 2012; 76: 1136-1144.

397. Bangalore S, Steg G, Deedwania P, et al. REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without

coronary artery disease. JAMA 2012; 308: 1340-1349.

398. Ozasa N, Kimura T, Morimoto T, et al. j-Cypher Registry Investigators. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical

outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2010; 106: 1225-1233.

399. 循環器病の診断と治療に関するガイドライン．心筋梗塞二次予防に関するガイドライン（2011年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2011

_ogawah_h.pdf（2013年1月閲覧）

400. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison

of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;

316: 1337-1343.

文献